2021 - CCG Updates & Insights
-
The Serendipitous Off-Target Explorer – Researcher Interview with Jason SheltzerIdentifying the “targets” for targeted therapy is a major challenge in precision medicine research. Dr. Jason Sheltzer discusses how he inadvertently uncovered mischaracterized cancer targets and what his findings may mean for cancer drug development.
-
Uncovering How HPV Alters the Genome in Ugandan Cervical Cancer PatientsThe molecular mechanisms by which HPV infection leads to cancer, especially in low- and middle-income countries experiencing high incidence and mortality rates, have yet to be clearly delineated. A recent genomic, epigenomic, and transcriptomic study of cervical tumors from Ugandan patients looks at specific types of HPV and the genomic alterations they cause.
-
Next-Gen Technologies for Next-Gen Cancer Models, a PANACEA Database for Identifying Drug Off-Targets, and Updates to the CTD^2 and HCMI Programs: February OCG e-NewsletterA new program developing technologies facilitating next-generation cancer model usage, new features and functions from the Cancer Target Discovery and Development (CTD^2) Program, an off-target discovery DREAM Challenge, and more from the February 2021 edition of the Office of Cancer Genomics (OCG) e-Newsletter.
-
NCI Genomic Data Commons: A Community Resource for Cancer ResearchA short time ago the Genomic Data Commons (GDC) was just a dream. CCG Director Lou Staudt describes what the GDC team has built so far: an interactive data system with genomic data processing pipelines for all types of researchers to use.